109 related articles for article (PubMed ID: 17512749)
1. Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington's disease stages.
Varani K; Bachoud-Lévi AC; Mariotti C; Tarditi A; Abbracchio MP; Gasperi V; Borea PA; Dolbeau G; Gellera C; Solari A; Rosser A; Naji J; Handley O; Maccarrone M; Peschanski M; DiDonato S; Cattaneo E
Neurobiol Dis; 2007 Jul; 27(1):36-43. PubMed ID: 17512749
[TBL] [Abstract][Full Text] [Related]
2. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
[TBL] [Abstract][Full Text] [Related]
3. TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease.
Reid SJ; van Roon-Mom WM; Wood PC; Rees MI; Owen MJ; Faull RL; Dragunow M; Snell RG
Brain Res Mol Brain Res; 2004 Jun; 125(1-2):120-8. PubMed ID: 15193429
[TBL] [Abstract][Full Text] [Related]
4. [The advances in research on phosphorylation of polyglutamine disease].
Zhou YF; Jiang H; Tang JG; Tang BS
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
[TBL] [Abstract][Full Text] [Related]
5. Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes.
Battista N; Bari M; Tarditi A; Mariotti C; Bachoud-Lévi AC; Zuccato C; Finazzi-Agrò A; Genitrini S; Peschanski M; Di Donato S; Cattaneo E; Maccarrone M
Neurobiol Dis; 2007 Jul; 27(1):108-16. PubMed ID: 17553686
[TBL] [Abstract][Full Text] [Related]
6. Role of proteolysis in polyglutamine disorders.
Tarlac V; Storey E
J Neurosci Res; 2003 Nov; 74(3):406-16. PubMed ID: 14598317
[TBL] [Abstract][Full Text] [Related]
7. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.
Wong HK; Bauer PO; Kurosawa M; Goswami A; Washizu C; Machida Y; Tosaki A; Yamada M; Knöpfel T; Nakamura T; Nukina N
Hum Mol Genet; 2008 Oct; 17(20):3223-35. PubMed ID: 18658163
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of polyglutamine disorders: aggregation revisited.
Michalik A; Van Broeckhoven C
Hum Mol Genet; 2003 Oct; 12 Spec No 2():R173-86. PubMed ID: 14504263
[TBL] [Abstract][Full Text] [Related]
9. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology.
Klejbor I; Stachowiak EK; Bharali DJ; Roy I; Spodnik I; Morys J; Bergey EJ; Prasad PN; Stachowiak MK
J Neurosci Methods; 2007 Sep; 165(2):230-43. PubMed ID: 17655935
[TBL] [Abstract][Full Text] [Related]
10. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model.
Bode FJ; Stephan M; Wiehager S; Nguyen HP; Björkqvist M; von Hörsten S; Bauer A; Petersén A
Behav Brain Res; 2009 Dec; 205(1):175-82. PubMed ID: 19573560
[TBL] [Abstract][Full Text] [Related]
11. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
[TBL] [Abstract][Full Text] [Related]
12. Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients.
Almeida S; Sarmento-Ribeiro AB; Januário C; Rego AC; Oliveira CR
Biochem Biophys Res Commun; 2008 Oct; 374(4):599-603. PubMed ID: 18625199
[TBL] [Abstract][Full Text] [Related]
13. Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases.
Liu CS; Cheng WL; Kuo SJ; Li JY; Soong BW; Wei YH
J Neurol Sci; 2008 Jan; 264(1-2):18-21. PubMed ID: 17720200
[TBL] [Abstract][Full Text] [Related]
14. Peripheral markers of autophagy in polyglutamine diseases.
Puorro G; Marsili A; Sapone F; Pane C; De Rosa A; Peluso S; De Michele G; Filla A; Saccà F
Neurol Sci; 2018 Jan; 39(1):149-152. PubMed ID: 29046994
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
[TBL] [Abstract][Full Text] [Related]
16. Spinocerebellar ataxia type 17 repeat in patients with Huntington's disease-like and ataxia.
Cellini E; Forleo P; Nacmias B; Tedde A; Bagnoli S; Piacentini S; Sorbi S
Ann Neurol; 2004 Jul; 56(1):163; author reply 163-4. PubMed ID: 15236416
[No Abstract] [Full Text] [Related]
17. A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain.
Curtis MA; Faull RL; Glass M
J Chem Neuroanat; 2006 Apr; 31(3):210-5. PubMed ID: 16533591
[TBL] [Abstract][Full Text] [Related]
18. [Clinical and genetic implications of dynamic mutations in neuropediatric practice].
Benítez J
Rev Neurol; 1999 Jan 1-15; 28(1):60-3. PubMed ID: 10101767
[TBL] [Abstract][Full Text] [Related]
19. Trinucleotide repeats: mechanisms and pathophysiology.
Cummings CJ; Zoghbi HY
Annu Rev Genomics Hum Genet; 2000; 1():281-328. PubMed ID: 11701632
[TBL] [Abstract][Full Text] [Related]
20. Huntington's disease-like 2 in Brazil--report of 4 patients.
Rodrigues GG; Walker RH; Brice A; Cazeneuve C; Russaouen O; Teive HA; Munhoz RP; Becker N; Raskin S; Werneck LC; Junior WM; Tumas V
Mov Disord; 2008 Nov; 23(15):2244-7. PubMed ID: 18816802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
